Comparison of capecitabine and 5-fluorouracil in chemoradiotherapy for locally advanced pancreatic cancer.

ABSTRACT:

Background

Although capecitabine has theoretical advantages in the pharmacokinetics, such as higher intratumoral and lower systemic concentration, relative to bolus 5-fluorouracil (5-FU), outcomes of chemoradiotherapy (CRT) with capecitabine or bolus 5-FU have not been directly compared in patients with locally advanced pancreatic cancer. Therefore, we retrospectively compared the outcomes, including toxicity, tumor response, and overall survival, of oral capecitabine plus radiotherapy (RT) with bolus 5-FU plus RT, in patients with locally advanced pancreatic cancer.

Methods

Between August 2006 and January 2012, 98 patients with locally advanced pancreatic cancer received CRT, with 52 receiving concurrent oral capecitabine and 46 receiving bolus injection of 5-FU. Primary tu

SUBMITTER: Kim YJ 

PROVIDER: S-EPMC3702484 | biostudies-literature | 2013 Jul

REPOSITORIES: biostudies-literature